Overview
Pulmonary Arterial Hypertension is treated with 19 medications in our database, including Ambrisentan, EPOPROSTENOL, BYQLOVI, Sterile Diluent for Treprostinil, Treprostinil, bosentan, and 14 more. 12 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Gilead, GlaxoSmithKline, Laurus, United Therapeutics, Actelion and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Pulmonary Arterial Hypertension treatment below.
Also known as:
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
10 eventsBOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
20 availableWINREVAIR
indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC),…
indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death
Flolan
FLOLAN is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity
Sildenafil
indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening
Sildenafil
indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening
Sildenafil
indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening
Epoprostenol
indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity
Opsynvi
chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III)
Tyvaso DPI
Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
Uptravi
Indicated for PAH to delay disease progression and reduce hospitalization risk.
Opsumit
Indicated for PAH to delay disease progression. Dual endothelin receptor antagonist.
Tyvaso
Indicated to improve exercise ability in PAH patients. Prostacyclin analog.
Tadalafil
Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability
Ambrisentan
Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening
Ventavis
Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms
Bosentan
Treatment of pulmonary arterial hypertension.
BYQLOVI
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Treprostinil, DILUENT
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Revonto
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Oxygen/Nitrogen 38/62
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Sterile Diluent for Treprostinil, Treprostinil
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Cardiology / Pulmonary Hypertension
Cardiology / Pulmonary Vascular Disease
Pulmonology / Pulmonary Vascular Disease
Pulmonology / Pulmonary Hypertension
Pulmonology / Pulmonary Vascular Disease
Cardiology / Pulmonary Hypertension
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
19 resourcesPAN Foundation — Pulmonary arterial hypertension
PAN Foundation
Pulmonary arterial hypertension
NORD Patient Assistance — Pulmonary arterial hypertension
NORD Patient Assistance
Pulmonary arterial hypertension
Good Days — Pulmonary arterial hypertension
Good Days
Pulmonary arterial hypertension
HealthWell Foundation — Pulmonary arterial hypertension
HealthWell Foundation
Pulmonary arterial hypertension
The Assistance Fund — Pulmonary arterial hypertension
The Assistance Fund
Pulmonary arterial hypertension
Patient Advocate Foundation — Pulmonary arterial hypertension
Patient Advocate Foundation
Pulmonary arterial hypertension
Patient Services Inc — Pulmonary arterial hypertension
Patient Services Inc
Pulmonary arterial hypertension
6 travel grants are also available for Pulmonary arterial hypertension patients — see Travel Grants below ↓
Travel Grants
6 grantsPAN Foundation Pulmonary Hypertension Copay Grant
PAN Foundation
Applicants must be receiving treatment for pulmonary hypertension in the United States and have health insurance that covers their qualifying prescribed medication. Eligibility also requires a household income at or below 500% of the Federal Poverty Level.
ONWARD Patient Support Program
UCB
The ONWARD program is available to patients aged 2 years and older who are prescribed FINTEPLA for Dravet syndrome or Lennox-Gastaut syndrome. It provides access to financial support resources, clinical education, and dedicated care coordination to assist with insurance and treatment navigation.
QuickRx Specialty Pharmacy Tyvaso Copay Assistance
QuickRx Specialty Pharmacy
Eligibility is based on having a valid prescription for FDA-approved PAH treatment and varies by insurance type, including commercial, Medicare/Medicaid, or uninsured status. Requirements typically include US residency, age 18 or older, and demonstrated financial need for specific foundation or manufacturer assistance.
Tyvaso Patient Assistance Program
Eligibility generally requires patients to be uninsured or underinsured, reside in the U.S., and demonstrate financial hardship. Specific programs mention income limits up to 500% of the Federal Poverty Level, though many evaluate applications on a case-by-case basis.
GSK for You Patient Assistance Program
GSK
Eligibility is determined by pharmaceutical manufacturers based on income limits, insurance status, and financial need, with specific thresholds like 300% FPL mentioned for certain medications. Programs typically require patients to be either commercially insured for co-pay assistance or uninsured/underinsured for free medication through patient assistance foundations.
Opsumit Patient Assistance Enrollment Form
Community
No community posts yet. Be the first to share your experience with Pulmonary arterial hypertension.
Start the conversation →Latest news about Pulmonary arterial hypertension
4 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pulmonary arterial hypertension
What is Pulmonary arterial hypertension?
Pulmonary Arterial Hypertension is treated with 19 medications in our database, including Ambrisentan, EPOPROSTENOL, BYQLOVI, Sterile Diluent for Treprostinil, Treprostinil, bosentan, and 14 more. 12 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Gilead, GlaxoSmithKline, Laurus, United Therapeutics, Actelion and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Pulmonary Arterial Hypertension treatment below.
Are there clinical trials for Pulmonary arterial hypertension?
Yes — 1 recruiting clinical trial is currently listed for Pulmonary arterial hypertension on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Pulmonary arterial hypertension?
25 specialists and care centers treating Pulmonary arterial hypertension are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Pulmonary arterial hypertension?
16 FDA-approved treatments and 20 patient support programs are currently tracked on UniteRare for Pulmonary arterial hypertension. See the treatments and support programs sections for copay assistance, eligibility, and contact details.